Bruce Cree, MD, PhD, MAS - Exploring the Convergence of Advances in S1P Receptor Modulation With Progress in Understanding Brain Atrophy and Cognition Measures in Multiple Sclerosis

Go online to PeerView.com/FUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, experts in neurology explore the mechanisms of action of S1PR modulators approved for the treatment of multiple sclerosis (MS), highlighting the similarities and differences among treatment options and reviewing the efficacy and safety data for these therapies and their potential effects on markers of treatment response or disease progression (eg, brain atrophy, neurofilament protein levels, cognitive test results). The burden, assessment, and management of cognitive impairment in MS, which occurs in over 50% of people with MS and can greatly affect patients’ functioning and quality of life, is also examined in this activity. The expert faculty also present and discuss patient case scenarios, through which they explore best practices in the care of patients with varied disease presentations and clinical contexts. Upon completion of this CE activity, participants will be able to: Describe the mechanisms of action for S1PR modulators approved for the treatment of MS in the context of disease pathophysiology, Recognize the therapeutic effects of S1PR modulators approved for the treatment of MS, including efficacy, safety, and tolerability, and the potential impact on emerging disease state markers (eg, brain atrophy, neurofilament protein, cognition), Use S1PR modulators appropriately, according to current recommendations and evidence, to meet treatment needs of individuals with MS.